Earnings ·
Reports Q3 net loss of $128M and raises full-year revenue guidance to $70M-$75M
RCUSArcus Biosciences, Inc.
Arcus Biosciences reported a third-quarter 2026 net loss of $128 million, or $1.00 per share, compared to a $135 million loss in the prior year period. Revenues fell to $9 million from $26 million as Gilead collaboration activities wind down. The company raised its full-year 2026 GAAP revenue guidance to between $70 million and $75 million. Cash, cash equivalents, and marketable securities stood at $694 million at quarter-end, supplemented by $288 million in gross proceeds from an October equity financing, providing a cash runway into 2029. Pipeline updates highlighted that enrollment in the Phase 3 PEAK-1 study is nearing completion, while the first-line PEAK-20 trial is expected to initiate by year-end 2026. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for cancer and immune diseases.